Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He is also the founder, CEO, & President of Centivax. He was formerly a Co-founder, CEO, and President of Distributed Bio, which he and his co-founders sold to Charles River Laboratories in 2020. During his time at Distributed Bio, he developed the core business model, research teams, and technologies that enabled the company to become profitable without investment.
As part of the acquisition agreement, he founded Centivax Inc and spun-out his assets in COVID-19 therapeutics, broad-spectrum vaccines, anti-venom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax.
.png)
